About
BreezeBio, formerly GenEdit, is a biotechnology company focused on developing genetic medicines through targeted in vivo delivery. It utilizes its proprietary NanoGalaxy® platform, which consists of non-viral, non-lipid hydrophilic nanoparticles (HNPs). These nanoparticles are engineered to deliver various genetic payloads, including mRNA, siRNA, and gene editors, to specific cell types and tissues, such as immune cells, heart, lung, and central nervous system.
Key facts
At-a-glance profile data
- Website
- breeze.bio
- Headquarters
- Alameda, California, US
- Founded
- 2016
- Employees
- 63
- Total funding
- $94M (Series B)
- Business model
- B2B2C
Funding rounds
Frequently asked
What does BreezeBio do?
The company is advancing an internal therapeutic pipeline with an initial focus on autoimmune diseases and oncology, with its lead candidate, BRZ-101, designed to restore immune tolerance in Type 1 diabetes. BreezeBio also engages in partnered programs to leverage its delivery technology.
How much funding has BreezeBio raised?
BreezeBio has raised a total of $94M in funding. The most recent round on record is Series B.
How many employees does BreezeBio have?
BreezeBio has approximately 63 people on record.